Cargando…

Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats

OBJECTIVE: To develop and evaluate zolmitriptan spanlastics (Zol SLs) as a brain-targeted antimigraine delivery system. Spanlastics (SLs) prepared using span 60: tween 80 (70:30%, respectively) gave the highest percentage of entrapment efficiency (EE%). MATERIALS AND METHODS: A total of 60 adult mal...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Nabarawy, Nagla Ahmed, Teaima, Mahmoud Hassan, Helal, Doaa Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877729/
https://www.ncbi.nlm.nih.gov/pubmed/31819367
http://dx.doi.org/10.2147/DDDT.S220473
_version_ 1783473395197804544
author El-Nabarawy, Nagla Ahmed
Teaima, Mahmoud Hassan
Helal, Doaa Ahmed
author_facet El-Nabarawy, Nagla Ahmed
Teaima, Mahmoud Hassan
Helal, Doaa Ahmed
author_sort El-Nabarawy, Nagla Ahmed
collection PubMed
description OBJECTIVE: To develop and evaluate zolmitriptan spanlastics (Zol SLs) as a brain-targeted antimigraine delivery system. Spanlastics (SLs) prepared using span 60: tween 80 (70:30%, respectively) gave the highest percentage of entrapment efficiency (EE%). MATERIALS AND METHODS: A total of 60 adult male Wistar albino rats were divided into six groups (n=10 rats/group). Group 1 (Control) comprised rats serving as a negative control. Group 2 was treated with glyceryl trinitrate (NTG) and served as the positive control. Groups 3 (NTG+Zol com), Group 4 (NTG+Zol sol) and Group 5 (NTG+Zol SLs) received commercial zolmitriptan orally, zolmitriptan solution intranasally and Zol SLs F5 intranasally, respectively, 30 min before NTG. Group 6 (Zol SLs) comprised normal rats that received only Zol SLs intranasally. RESULTS: We found decreased T(max), increased C(max), AUC(0–6), AUC(0–∞ and) ameliorated behaviour in rats (head scratching) treated with intranasal SLs compared to oral commercial zolmitriptan. CONCLUSION: Our study substantiates the enhanced efficacy of Zol SLs in brain targeting for migraine treatment.
format Online
Article
Text
id pubmed-6877729
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68777292019-12-09 Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats El-Nabarawy, Nagla Ahmed Teaima, Mahmoud Hassan Helal, Doaa Ahmed Drug Des Devel Ther Original Research OBJECTIVE: To develop and evaluate zolmitriptan spanlastics (Zol SLs) as a brain-targeted antimigraine delivery system. Spanlastics (SLs) prepared using span 60: tween 80 (70:30%, respectively) gave the highest percentage of entrapment efficiency (EE%). MATERIALS AND METHODS: A total of 60 adult male Wistar albino rats were divided into six groups (n=10 rats/group). Group 1 (Control) comprised rats serving as a negative control. Group 2 was treated with glyceryl trinitrate (NTG) and served as the positive control. Groups 3 (NTG+Zol com), Group 4 (NTG+Zol sol) and Group 5 (NTG+Zol SLs) received commercial zolmitriptan orally, zolmitriptan solution intranasally and Zol SLs F5 intranasally, respectively, 30 min before NTG. Group 6 (Zol SLs) comprised normal rats that received only Zol SLs intranasally. RESULTS: We found decreased T(max), increased C(max), AUC(0–6), AUC(0–∞ and) ameliorated behaviour in rats (head scratching) treated with intranasal SLs compared to oral commercial zolmitriptan. CONCLUSION: Our study substantiates the enhanced efficacy of Zol SLs in brain targeting for migraine treatment. Dove 2019-11-21 /pmc/articles/PMC6877729/ /pubmed/31819367 http://dx.doi.org/10.2147/DDDT.S220473 Text en © 2019 El-Nabarawy et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
El-Nabarawy, Nagla Ahmed
Teaima, Mahmoud Hassan
Helal, Doaa Ahmed
Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats
title Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats
title_full Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats
title_fullStr Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats
title_full_unstemmed Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats
title_short Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats
title_sort assessment of spanlastic vesicles of zolmitriptan for treating migraine in rats
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877729/
https://www.ncbi.nlm.nih.gov/pubmed/31819367
http://dx.doi.org/10.2147/DDDT.S220473
work_keys_str_mv AT elnabarawynaglaahmed assessmentofspanlasticvesiclesofzolmitriptanfortreatingmigraineinrats
AT teaimamahmoudhassan assessmentofspanlasticvesiclesofzolmitriptanfortreatingmigraineinrats
AT helaldoaaahmed assessmentofspanlasticvesiclesofzolmitriptanfortreatingmigraineinrats